Journals / The Journal of Pediatric Research / 2022 / Cilt: 9 - Sayı: 1

Thiopurine-S-Methyltransferase Gene Polymorphism and Drug-related Toxicity in Children Treated for Acute Leukemia and Non-Hodgkin’s Lymphoma

Pages
60–65
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We did not find any relationship between severe hematologic/hepatic toxicities and TPMT gene polymorphisms.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Thiopurine S-methyltransferase (TPMT) is an essential enzyme in the metabolism of thiopurine drugs, and its activity may change due to different polymorphisms in the TPMT gene.
📊
Key Findings & Data:Materials and Methods: Sixty-seven pediatric AL/NHL patients and 84 healthy children were evaluated.
💡
Conclusion & Impact:We did not find any relationship between severe hematologic/hepatic toxicities and TPMT gene polymorphisms.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Thiopurine S-methyltransferase (TPMT) is an essential enzyme in the metabolism of thiopurine drugs, and its activity may change due to different polymorphisms in the TPMT gene. The TPMT gene has different genetic polymorphisms in different ethnic groups. This study aimed to determine the frequency of TPMT polymorphisms in children with acute leukemia/non-Hodgkin lymphoma (AL/NHL) and healthy children and to evaluate their association with severe toxicities in the study population. Materials and Methods: Sixty-seven pediatric AL/NHL patients and 84 healthy children were evaluated. Genotyping for the TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*4, TPMT*5, TPMT*6, and TPMT*7 alleles were performed by the real-time polymerase chain reaction technique. The number of grade 3 or higher hematologic and hepatic toxicities were recorded from the patient charts. Results: In the AL/NHL patients, we found that the patients had generally wild-type TPMT*1 allele in 80.6%, whereas TPMT*2 (238G>C) was seen in 1.5%, TPMT*3A (c.460G>A and c.719A>G) in 0%, and TPMT*3B polymorphisms (460G>A) in 17.9%. We found wild-type TPMT*1 allele in 98.8% and TPMT*3B polymorphisms (460G>A) in 1.2% of the healthy volunteers. Grade ≥3 myelosuppression developed in 22/54 patients with the wild type allele, and it developed in 5/12 patients with TPMT*3B allele. Six (8.9%) patients had grade ≥3 aspartate aminotransferase elevations, 17 (25%) patients had grade ≥3 alanine transaminase elevations (1-5 times), and 42 patients had (62.6%) grade ≥3 total bilirubin elevations. Conclusion: TPMT*3B polymorphism was the most common allele detected in our study group. This allele frequency is very high in comparison to other studies from our country and it was over-represented in comparison to the healthy volunteers. We did not find any relationship between severe hematologic/hepatic toxicities and TPMT gene polymorphisms.

🔖

Cite This Article

KOSOVA, B., KURUGÖL, Z., ATASEVEN, E., KANTAR, M., AKTAN, Ç. (2022). Thiopurine-S-Methyltransferase Gene Polymorphism and Drug-related Toxicity in Children Treated for Acute Leukemia and Non-Hodgkin’s Lymphoma. The Journal of Pediatric Research, Cilt: 9 - Sayı: 1, 60–65. https://ajindex.com/articles/597858

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Azimi F, Jafariyan M, Khatami S, Mortazavi Y, Azad M. Assessment of thiopurine-based drugs according to thiopurine- S-methyltransferase genotype in patients with acute lymphoblastic leukemia. Iran J Ped Hematol Oncol 2014; 4:32-8
  2. Dean L, Kane M. Mercaptopurine Therapy and TPMT and NUDT15 Genotype. In: Pratt VM, Scott SA, Pirmohamed M, et al (eds). Medical Genetics Summaries: Bethesda, National Center for Biotechnology Information (US), 2012
  3. Szumlanski C, Otterness D, Her C, et al. Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol 1996; 15:17-30
  4. Tai HL, Krynetski EY, Schuetz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) en-coded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997; 10:94:6444-9
  5. Wang L, Nguyen TV, McLaughlin RW, Sikkink LA, Ramirez- Alvarado M, Weinshilboum RM. Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A 2005; 28:102:9394-9. 6. https://ctep.cancer.gov/protocoldevelopment/electronic_ applications/docs/ctcae_v5_quick_reference_5x7.pdf Published: November 27, 2017
  6. Sayitoğlu MA, Yıldız İ, Hatırnaz Ö, Özbek U. Common Cytochrome p4503A (CYP3A4 and CYP3A5) and Thiopurine S-methyl trans-ferase (TPMT) polymorphisms in Turkish population. Turk J Med Sci 2006; 36:11-5
  7. Tumer TB, Ulusoy G, Adali O, Sahin G, Gozdasoglu S, Arinç E. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia. Am J Hematol 2007; 82:906-10
  8. Akın DF, Aşlar-Öner D, Kürekçi E, Akar N. Frequency of thiopurine S-methyltransferase gene variations in Turkish children with acute leukemia. Turk J Pediatr 2018; 60:147-52
  9. Moreno-Guerrero SS, Ramírez-Pacheco A, Dorantes-Acosta EM, Medina-Sanson A. Analysis of genetic polymorphisms of thiopurine S-methyltransferase (TPMT) in Mexican pediatric patients with cancer. Rev Invest Clin 2013; 65:156-64
  10. Jiménez-Morales S, Ramírez-Florencio M, Mejía-Aran guré JM, et al. Analysis of thiopurine S-methyltransferase deficient alleles in acute lymphoblastic leukemia patients in Mexican patients. Arch Med Res 2016; 47:615-22
  11. Corominas H, Domènech M, del Río E, Gich I, Domingo P, Baiget M. Frequency of thiopurine S-methyltransferase alleles in different e